Neoadjuvant chemo for triple negative breast cancers – pro
Triple-negative breast cancer (TNBC) remains the poorest-prognosis breast cancer (BC) subtype. In the early stages, the use of neoadjuvant systemic treatment (NST) is the standard of care in TNBCs and patients who achieve a pathological complete response (pCR) with primary therapy have improved survival outcomes. It is not known how small must the primary cancer be to not obtain this advantage. Standard neoadjuvant regimens include anthracyclines, taxanes, and cyclophosphamide. Platinum-based chemotherapy has been proposed but is not yet recommended by available guidelines
Omarini C, Guaitoli G, Pipitone S, et al. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res. 2018;10:91-103.